Cytek BioSciences, Inc. (CTKB): Price and Financial Metrics


Cytek BioSciences, Inc. (CTKB): $13.92

0.71 (+5.37%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CTKB Stock Price Chart Interactive Chart >

Price chart for CTKB

CTKB Price/Volume Stats

Current price $13.92 52-week high $28.70
Prev. close $13.21 52-week low $13.01
Day low $13.39 Volume 89,179
Day high $14.08 Avg. volume 175,672
50-day MA $18.39 Dividend yield N/A
200-day MA $0.00 Market Cap 1.86B

Cytek BioSciences, Inc. (CTKB) Company Bio


Cytek Biosciences, Inc. engages in the manufacture and sale of cell analysis solutions for clinical and biomedical research in the fields of drug discovery, genomics, immuno-oncology, immuno-profiling, infectious diseases, inflammatory diseases, and multi-site standardization applications. Its instruments include the Aurora and Northern Lights systems, which are flow cytometers to deliver cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. The company also offers cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. Its customers include pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. Cytek Biosciences, Inc. was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. The company was incorporated in 2014 and is headquartered in Fremont, California.


CTKB Latest News Stream


Event/Time News Detail
Loading, please wait...

CTKB Latest Social Stream


Loading social stream, please wait...

View Full CTKB Social Stream

Latest CTKB News From Around the Web

Below are the latest news stories about Cytek Biosciences Inc that investors may wish to consider to help them evaluate CTKB as an investment opportunity.

Cytek® Biosciences Expands Fremont Headquarters, Tripling Its Manufacturing Capacity

Operations to Accommodate Increasing Demand for Cell Analysis SolutionsFREMONT, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that it has opened a new facility in Fremont, California – tripling its current manufacturing capacity in order to meet growing global demand for cell analysis solutions. In addition to the new Fremont location, Cytek has also opened new offices in Seattle, Washington, which are

Yahoo | January 5, 2022

Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ...

New York, NY, based Investment company Orbimed Advisors Llc (Current Portfolio) buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, HCA Healthcare Inc, Erasca Inc, sells Prelude Therapeutics Inc, Aurinia Pharmaceuticals Inc, Ascendis Pharma A/S, Natera Inc, Anthem Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Orbimed Advisors Llc.

Yahoo | December 24, 2021

Zacks Investment Research Lowers Cytek BioSciences (NASDAQ:CTKB) to Hold

Cytek BioSciences (NASDAQ:CTKB) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report released on Tuesday, Zacks.com reports. According to Zacks, Cytek Biosciences Inc provides cell analysis solutions. The company developed high-resolution, high-content and high-sensitivity cell analysis technology called Full Spectrum Profiling. Cytek Biosciences Inc is based in []

Transcript Daily | December 21, 2021

Cytek BioSciences (NASDAQ:CTKB) Lifted to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Cytek BioSciences (NASDAQ:CTKB) from a hold rating to a buy rating in a research note issued to investors on Thursday, Zacks.com reports. Zacks Investment Research currently has $21.00 target price on the stock. According to Zacks, Cytek Biosciences Inc provides cell analysis solutions. The company developed high-resolution, high-content and []

Dakota Financial News | December 19, 2021

Now Is A Good Time To Buy Cytek Biosciences Inc. (NASDAQ: CTKB)

During the last session, Cytek Biosciences Inc. (NASDAQ:CTKB)s traded shares were 0.9 million. At the end of the trading day, the stocks price was $17.65, reflecting an intraday gain of 1.44% or $0.25. The 52-week high for the CTKB share is $28.70, that puts it down -62.61 from that peak though still a striking 3.06% Now Is A Good Time To Buy Cytek Biosciences Inc. (NASDAQ: CTKB) Read More »

Marketing Sentinel | December 18, 2021

Read More 'CTKB' Stories Here

CTKB Price Returns

1-mo -17.58%
3-mo -41.83%
6-mo -25.80%
1-year N/A
3-year N/A
5-year N/A
YTD -14.71%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6998 seconds.